- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07635108
MR-guided Single-fraction SBRT for Nodal Oligorecurrent Prostate Cancer (PINPOINT) (PINPOINT)
Improved MR-Guided Single-fraction Stereotactic Sblative Radiotherapy in Pelvic and Abdominal Nodal Oliorecurrent Prostate Cancer
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
PINPOINT is a prospective, investigator-initiated, single-centre, single-arm phase 2 trial of single-fraction MR-guided SBRT in patients with nodal oligorecurrent prostate cancer. Eligible men have PSMA-PET/CT-verified nodal relapse in the pelvis or abdomen following curatively intended local treatment.
All patients are simulated with MRI in treatment position and treated with 24 Gy in 1 fraction to the gross tumour volume (GTV) using inverse-planned step-and-shoot IMRT on an MR-linac. No CTV margin is added (CTV = GTV); PTV margins account for motion and set-up uncertainty. Normal-tissue constraints are prioritised over target coverage.
The primary endpoint is cumulative CTCAE v5 grade ≥4 treatment-related toxicity within 6 months. Sample size follows a Simon two-stage design (H0: grade 4-5 TRAE rate 15%; H1: 4%; one-sided α = 5%, power 80%), with an interim analysis after 6-month follow-up of the first 16 patients and a total of 48 patients. Follow-up continues for 5 years. Toxicity (CTCAE v5), quality of life (EQ-5D-5L, EORTC QLQ-C30) and patient-reported outcomes (PRO-CTCAE) are collected at baseline and through follow-up; PSA and PSMA-PET/CT (on rising PSA) follow standard of care.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Kristine S Nielsen, MD
- Telefoonnummer: +45 31269894
- E-mail: kristine.skovly.nielsen@rsyd.dk
Studie Contact Back-up
- Naam: Tine Schytte, Professor
- Telefoonnummer: +45 21421114
- E-mail: tine-schytte@rsyd.dk
Studie Locaties
-
-
-
Odense, Denemarken
- Department of Oncology, Odense University Hospital
-
Contact:
- Kristine S Nielsen, MD
- Telefoonnummer: +45 31269894
- E-mail: kristine.skovly.nielsen@rsyd.dk
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Age ≥ 18 years
- Signed informed consent
- Histologically proven initial diagnosis of adenocarcinoma of the prostate
- ECOG performance status 0-2
- Biochemical recurrence after curatively intended local treatment (radical prostatectomy and/or radiotherapy), with PSMA-PET/CT-verified nodal relapse in the pelvis or abdomen
- Any additional sites of disease beyond the protocol-specified target lymph nodes must be considered suitable for ablative treatment
- Life expectancy > 6 months
- Lymph node size ≤ 2 cm
Exclusion Criteria:
- Medical contraindications to MRI
- Inability to tolerate the physical set-up required for SABR
- Overlap between prior radiation fields and the current target area leading to high risk of clinically significant normal-tissue injury
- Contraindications to pelvic radiotherapy (chronic pelvic inflammatory bowel disease)
- Uncontrolled intercurrent illness
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Single-fraction MR-guided SBRT
All participants receive 24 Gy in a single fraction to the GTV, delivered with MR-guided SBRT.
|
Participants will receive 24 Gy in 1 fraction to a lymph node.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of Participants with cumulative CTCAE v5.0 grade ≥4 treatment-related adverse events
Tijdsspanne: Within 6 months after completion of radiotherapy
|
The NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 measures side-effects.
Possible scores range from 0-5, with higher scores indicating a worse outcome.
|
Within 6 months after completion of radiotherapy
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of participants with late adverse events (CTCAE v5.0)
Tijdsspanne: 1, 1,5, 2, 3 and 5 years
|
The NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 measures side-effect. Possible scores range from 0-5, with higher scores indicating a worse outcome. |
1, 1,5, 2, 3 and 5 years
|
|
Percentage of participants free from local progression (PSMA-PET/CT-verified), estimated by time-to-event analysis
Tijdsspanne: From radiotherapy until local progression or last follow-up, up to 5 years
|
Defined as freedom from PSMA-verified relapse within the treated area.
In the case of significant increase in PSA, a PSMA will be performed as to local guidelines.
Local control will be evaluated at a lesion level, lesion by lesion.
Within the treated area is defined as within or adjacent to the planning target volume (PTV).
|
From radiotherapy until local progression or last follow-up, up to 5 years
|
|
Median clinical progression-free survival
Tijdsspanne: From radiotherapy up to 5 years
|
Defined as time from inclusion to any new node or distant metastases recurrence.
|
From radiotherapy up to 5 years
|
|
Median time to initiation of palliative ADT (ADT-free survival)
Tijdsspanne: From inclusion up to 5 years
|
ADT-free survival is defined as the time from trial randomization to start of hormonal treatment
|
From inclusion up to 5 years
|
|
Number of participants with acute adverse events (CTCAE v5.0), by maximum grade
Tijdsspanne: Within 6 months after radiotherapy
|
The NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 measures side-effects.
Possible scores range from 0-5, with higher scores indicating a worse outcome.
|
Within 6 months after radiotherapy
|
|
Median overall survival
Tijdsspanne: From inclusion up to 5 years
|
Overall survival is defined as time form inclusion to death from any cause
|
From inclusion up to 5 years
|
|
Mean change from baseline in EQ-5D-5L index (utility) score
Tijdsspanne: Baseline, 2 weeks, 3,6 and 12 months
|
The EQ-5D-5L is a standardized, validated generic instrument for health-related quality of life.
It comprises five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each with five response levels.
Responses are converted to a single summary index (utility) score using a country-specific (Danish) value set, anchored at 1 = full health and 0 = death, with negative values possible for health states considered worse than death; higher scores indicate better health-related quality of life.
The outcome is reported as the mean change from baseline in the EQ-5D-5L index score at each assessment time point.
|
Baseline, 2 weeks, 3,6 and 12 months
|
|
Mean change from baseline in EORTC QLQ-C30 Global Health Status / QoL scale score
Tijdsspanne: Baseline, 2 weeks, 3, 6 and 12 months
|
The EORTC QLQ-C30 (version 3.0) is a validated cancer-specific questionnaire for assessing health-related quality of life in clinical trials.
It contains 30 items comprising a global health status / quality of life scale, five functional scales (physical, role, emotional, cognitive, and social functioning), three symptom scales (fatigue, nausea/vomiting, and pain), and several single-item symptom and financial-impact measures.
Raw scores are linearly transformed to a 0-100 scale according to the EORTC scoring manual; for the global health status / QoL scale a higher score indicates better quality of life.
This outcome is reported as the mean change from baseline in the global health status / QoL scale score at each assessment time point.
|
Baseline, 2 weeks, 3, 6 and 12 months
|
|
Number of participants reporting symptomatic adverse events as assessed by PRO-CTCAE
Tijdsspanne: Baseline, 2 weeks, 3,6 and 12 months
|
PRO-CTCAE (Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events) is a validated patient-reported measurement system developed by the NCI to capture symptomatic toxicity in cancer clinical trials.
A predefined subset of PRO-CTCAE items is used in this trial.
Each symptom is rated by the patient over the prior 7 days across the applicable attributes - frequency (never to almost constantly), severity (none to very severe), and/or interference with usual or daily activities (not at all to very much) - each on a 5-point ordinal scale (scored 0-4).
The outcome is reported as the number of participants in each response category per item and attribute at each assessment time point.
|
Baseline, 2 weeks, 3,6 and 12 months
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Genitale ziekten
- Pathologische processen
- Genitale neoplasmata, mannelijk
- Urogenitale neoplasmata
- Neoplasmata per site
- Neoplasmata
- Genitale ziekten, man
- Prostaat Ziekten
- Mannelijke urogenitale ziekten
- Neoplastische processen
- Neoplasma metastase
- Pathologische aandoeningen, tekenen en symptomen
- Prostaatneoplasmata
- Lymfatische metastase
Andere studie-ID-nummers
- OP-2499
- S-20250058 (Andere identificatie: Ethics committee)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .